SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, reported a net income of $13.3 million for the year ended December 31, 2025, a significant turnaround from the net loss of $34.1 million reported for the previous year. This improvement was primarily driven by a $57.4 million increase in the fair value of warrant liabilities. The company's revenue remained at zero, compared to $1.3 million in grant revenue in 2024, due to the termination of a JPEO Rapid Response Contract.
Research and development expenses increased by 13.6% to $34.4 million in 2025, driven by increased clinical trial expenses and salaries and benefits, offset by a decrease in outside lab services and overhead costs. General and administrative expenses also saw a slight increase of 4.4% to $14.6 million, mainly due to higher administrative support fees, offset by a decrease in salaries and benefits. The company's cash, cash equivalents, and investments totaled $143.5 million as of December 31, 2025, compared to $20.8 million the previous year, primarily due to the Series B Offering.
Key operational developments included the initiation of a global Phase 2b clinical trial, called the SAFEGUARD study, for its lead product candidate, SAB-142, in Q3 2025, with the first patient dosed in December 2025. The company also confirmed its intent with the FDA to utilize the data from this study as primary evidence for future regulatory approval. As of December 31, 2025, the company had 86 full-time employees, with a focus on research and development activities.
Looking ahead, SAB Biotherapeutics anticipates continued investment in its business, particularly in research and development for SAB-142 and other product candidates. The company expects to incur operating losses for the foreseeable future and will require additional capital to fund its operations. While the ongoing Phase 2b study is designed to provide robust evidence of safety and efficacy, the FDA may require additional supportive clinical trial(s) beyond this study to establish substantial evidence sufficient for BLA approval.
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics is a clinical-stage biopharmaceutical company developing human polyclonal immunotherapeutic antibodies (hIgG) for immunology disorders. Its proprietary platform produces targeted, high-potency antibodies using genetically engineered transchromosomic cattle, enabling scalable, plasma-free manufacturing. The company focuses on autoimmune diseases like type 1 diabetes, aiming for disease-modifying therapies with improved safety, re-dosing potential, and addressing unmet medical needs.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.